In poor IVF responders, cancellation, stimulation duration, gonadotrophin use and follicle, oocyte and embryo counts did not differ significantly between cetrorelix and buserelin.
In plain wordsIn poor IVF responders, the listed stimulation outcomes did not differ significantly between cetrorelix and buserelin.
- Peptide
- Cetrorelix
- Outcome
- No significant changeCycle cancellation, stimulation duration, gonadotrophin use and follicle, oocyte and embryo counts
- Study
n = 66
- Comparator
- Buserelin acetate 600 microg daily
- Outcome group
- Sex hormones and fertility · Reproductive and sexual health
- Studied dose
- 0.25 mg dailyAs given in this study (human).
Source sentences
There were no significant differences in the cycle cancellation rates, duration of stimulation, consumption of gonadotrophins, and mean numbers of mature follicles, oocytes and embryos obtained.
3 context sentences(design, population, supporting numbers)
This is the first published report of a prospective, randomized, controlled trial comparing a fixed, multi-dose GnRH antagonist protocol with a long GnRH agonist protocol in poor responders undergoing IVF.
Sixty-six poor responders were randomized into two groups: the study group received 0.25 mg of cetrorelix daily starting on day 6 of stimulation; the control group received 600 microg of buserelin acetate daily starting in the mid-luteal phase of the preceding cycle.
Both groups were given a fixed dose of recombinant FSH (300 IU daily) for stimulation.